Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis

Area of Science:

• Immunology
• Metabolomics
• Infectious Diseases

Background:

• Leprosy's clinical spectrum and pathogenesis are driven by the host immune response to Mycobacterium leprae.
• Metabolomics studies reveal links between leprosy manifestations and altered polyunsaturated fatty acid (PUFA) metabolism.
• The role of PUFA-derived lipid mediators in chronic infections like leprosy remains poorly understood.

Purpose of the Study:

• To review and hypothesize the role of ω3 and ω6 PUFA metabolism in leprosy pathogenesis.
• To explore how lipid mediators influence innate and adaptive immune responses in leprosy.
• To model the interactions between lipid mediators and immune responses affecting leprosy outcomes.

Main Methods:

• Review of existing literature on PUFA metabolism, lipid mediators, and leprosy.
• Analysis of metabolomics data linking PUFA alterations to leprosy clinical forms.
• Development of conceptual models for lipid mediator-immune cell interactions.

Main Results:

• Specialized pro-resolving lipid mediators (SPMs) may down-modulate immune responses against M. leprae.
• Imbalances in pro-inflammatory versus SPMs are linked to significant shifts in leprosy pathogenesis.
• Altered ω3 and ω6 PUFA metabolism is strongly associated with leprosy's clinical presentation.

Conclusions:

• ω3 and ω6 PUFA metabolism significantly influences leprosy pathogenesis.
• Lipid mediator interactions with the immune system are critical determinants of leprosy outcomes.
• Further research into these interactions could reveal new therapeutic targets for leprosy.